Leukocyte count and vascular risk in symptomatic intracranial atherosclerosis

Cerebrovascular Diseases

Volumn 24, Issue 2-3, 2007, Pages 283-288

  Ovbiagele, Bruce ^a,d   Lynn, Michael J ^b   Saver, Jeffrey L ^a   Chimowitz, Marc I ^c  

^a UCLA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intracranial atherosclerosis; Leukocytes; Stroke, ischemic

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ADULT; ARTICLE; BODY MASS; BRAIN ATHEROSCLEROSIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; CONSTRICTION, PATHOLOGIC; FEMALE; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WARFARIN;

EID: 34548085680     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105681     Document Type: Article

References (32)

1. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-1482.
2. Ridker P, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
3. Grau A, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W: Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004;35:1147-1152.
4. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
5. Kannel W, Anderson K, Wilson PW: White blood cell count and cardiovascular disease: insights from the Framingham study. JAMA 1992;267:1253-1256.
6. Margolis K, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH, Howard BV, Assaf AR, Prentice R: Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005;165:500-508.
7. Noto D, Barbagallo CM, Cavera G, Cefalu AB, Caimi G, Marino G, Lo Coco L, Caldarella R, Notarbartolo A, Averna MR: Leukocyte count, diabetes mellitus and age are strong predictors of stroke in a rural population in Southern Italy: an 8-year follow-up. Atherosclerosis 2001;157:225-231.
8. Elkind M, Sciacca RR, Boden-Albala B, Rundek T, Paik MC, Sacco RL: Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology 2005;64:2121-2125.
9. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA: Leukocytes and the risk of ischemic diseases. JAMA 1987;257:2318-2324.
10. Carlos T, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
11. Moreno P, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994;90:775-778.
12. Lowe G, Machado SG, Krol WF, Barton BA, Forbes CD: White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985;54:700-703.
13. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE: Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 2004;33:71-77.
14. Chimowitz M, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-1316.
15. Prentice R, Szatrowski TP, Kato H, Mason MW: Leukocyte counts and cerebrovascular disease. J Chronic Dis 1982;35:703-714.
16. Grau A, Buggle F, Becher H, Werle E, Hacke W: The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996;82:245-255.
17. Hansen L, Grimm RH, Neaton JD: The relationship of white blood cell count to other cardiovascular risk factors. Int J Epidemiol 1990;19:881-888.
18. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
19. Yarnell J, Sweetnam PM, Rogers S, Elwood PC, Bainton D, Baker IA, Eastham R, O'Brien JR, Etherington MD: Some long-term effects of smoking on the haemostatic system: a report from the Caerphilly and Speedwell collaborative surveys. J Clin Pathol 1987;40:909-913.
20. Nieto F, Szklo M, Folsom AR, Rock R, Mercuri M: Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1992;136:525-537.
21. Friedman G, Tekawa I, Grimm RH, Manolio T, Shannon SG, Sidney S: The leucocyte count: correlates and relationship to coronary risk factors: The CARDIA study. Int J Epidemiol 1990;19:889-893.
22. Ridker P, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
23. Collett D: Modeling Survival Data in Medical Research, ed 2. Boca Raton, Chapman & Hall/CRC, 2003, p 83.
24. Pearson T, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003;107:499-511.
25. Fuster V: Lewis A Conner memorial lecture - Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2146.
26. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
27. Grimm R, Neaton JD, Ludwig W: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985;254:1932-1937.
28. Yarnell J, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-844.
29. Lee C, Folsom AR, Nieto FJ, Chambless LE, Shahar E, Wolfe DA: White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001;154:758-764.
30. McGrath C, Hitchcock DC, Van Assendelft OW: Total white blood cell counts for persons ages 1-74 years with differential leukocyte counts for adults ages 25-74 years. Vital Health Stat 11 1982;220:1-36.
31. Stewart R, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, West MJ, Colquhoun DM, Tonkin AM: White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation 2005;111:1756-1762.
32. Ridker P, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E; Cholesterol and Recurrent Events (CARE) investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.